| P50 | author | Xuan Zhang | Q56374184 |
| P2093 | author name string | Lidan Zhao | |
| | Linfang Huang | |
| P2860 | cites work | Emerging Functions of RANKL in Lymphoid Tissues | Q21131222 |
| | Commitment to the B-lymphoid lineage depends on the transcription factor Pax5 | Q22010683 |
| | Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations | Q24310432 |
| | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 |
| | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 |
| | A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL | Q24799036 |
| | Osteoimmunology: the study of the relationship between the immune system and bone tissue | Q26996266 |
| | Denosumab: a novel antiresorptive drug for osteoporosis | Q28082084 |
| | Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis | Q28118730 |
| | Bone versus immune system | Q28140389 |
| | TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 |
| | RANK-L and RANK: T cells, bone loss, and mammalian evolution | Q28203468 |
| | Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis | Q28246778 |
| | A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis | Q28255805 |
| | TLR5, a novel mediator of innate immunity-induced osteoclastogenesis and bone loss | Q28265502 |
| | RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 |
| | Cytokines in the pathogenesis of rheumatoid arthritis | Q28303865 |
| | Autocrine regulation of interferon gamma in mesenchymal stem cells plays a role in early osteoblastogenesis | Q28304548 |
| | Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. | Q28506586 |
| | Immune complexes regulate bone metabolism through FcRγ signalling | Q28512966 |
| | TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Role of osteopontin in cellular signaling and toxicant injury | Q28594622 |
| | Osteoblastic cells regulate the haematopoietic stem cell niche | Q29615007 |
| | Identification of the haematopoietic stem cell niche and control of the niche size | Q29615008 |
| | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 |
| | Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus | Q33269870 |
| | Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis | Q33579424 |
| | Role of osteopontin in amplification and perpetuation of rheumatoid synovitis | Q33700555 |
| | The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. | Q33794960 |
| | BCL6 is critical for the development of a diverse primary B cell repertoire | Q33902336 |
| | Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. | Q33966602 |
| | Generation and culture of osteoclasts | Q34171862 |
| | T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair | Q34328599 |
| | Efficient osteoclast differentiation requires local complement activation | Q34374041 |
| | Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression | Q34451146 |
| | Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12 function in the hematopoietic stem cell endosteal niche | Q34516778 |
| | Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells | Q34576335 |
| | Wnt signaling: a key regulator of bone mass | Q34583328 |
| | Abatacept treatment for rheumatoid arthritis | Q34588972 |
| | DAP12 overexpression induces osteopenia and impaired early hematopoiesis | Q34775668 |
| | Novel immunostimulatory effects of osteoclasts and macrophages on human γδ T cells. | Q34906361 |
| | Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β. | Q35172785 |
| | Requirement for NF-kappaB in osteoclast and B-cell development | Q35199657 |
| | Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells | Q40277201 |
| | Pax5-deficient mice exhibit early onset osteopenia with increased osteoclast progenitors | Q40489394 |
| | Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion | Q40590532 |
| | Osteoprotegerin-Mediated Homeostasis of Rank+ Thymic Epithelial Cells Does Not Limit Foxp3+ Regulatory T Cell Development. | Q40646125 |
| | Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors | Q40727130 |
| | IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro | Q40814402 |
| | Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. | Q41121255 |
| | IL-10 critically modulates B cell responsiveness in Rankl-/- mice. | Q41137165 |
| | Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse | Q41205540 |
| | Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts | Q41773356 |
| | Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction | Q41927546 |
| | Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation | Q42219222 |
| | Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways | Q42494588 |
| | Bcl6 promotes osteoblastogenesis through Stat1 inhibition | Q42831214 |
| | Periodontitis in RA-the citrullinated enolase connection. | Q42916208 |
| | Mice lacking c-fos have normal hematopoietic stem cells but exhibit altered B-cell differentiation due to an impaired bone marrow environment | Q43181439 |
| | Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse | Q43681246 |
| | Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis | Q44688981 |
| | Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts | Q45325523 |
| | Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. | Q45905113 |
| | The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue | Q46286533 |
| | Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses | Q46891798 |
| | TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis | Q47789840 |
| | Tendency towards erosive regression on magnetic resonance imaging at 12 months in rheumatoid arthritis patients treated with rituximab | Q47820189 |
| | Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. | Q50335960 |
| | Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. | Q50912728 |
| | IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL | Q51027178 |
| | Interferon-γ plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. | Q51506098 |
| | Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. | Q51756072 |
| | The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. | Q51949099 |
| | Osteoclasts support the survival of human plasma cells in vitro. | Q51965738 |
| | Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. | Q52537176 |
| | Osteoclast-derived complement component 3a stimulates osteoblast differentiation. | Q53069661 |
| | Regulatory T cells protect from local and systemic bone destruction in arthritis. | Q53294686 |
| | The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. | Q53453365 |
| | IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model. | Q53464291 |
| | CTLA-4 directly inhibits osteoclast formation | Q56900321 |
| | Treg cells suppress osteoclast formation: a new link between the immune system and bone | Q56900960 |
| | Immune Interactions with CD4+ T Cells Promote the Development of Functional Osteoclasts from Murine CD11c+ Dendritic Cells | Q57184758 |
| | Receptor Activator of NF- B Ligand and Osteoprotegerin Regulate Proinflammatory Cytokine Production in Mice | Q57184804 |
| | Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation | Q57253491 |
| | Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial | Q57752107 |
| | Bone and haematopoietic defects in mice lacking c-fos | Q58326969 |
| | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ | Q59064307 |
| | Osteoimmunology and bone homeostasis: relevance to spondyloarthritis | Q38109578 |
| | Osteoclasts in RA: diverse origins and functions | Q38111507 |
| | Immune cells and bone: coupling goes both ways. | Q38134126 |
| | Tight relationships between B lymphocytes and the skeletal system | Q38204107 |
| | Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis | Q38458004 |
| | Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells | Q38506162 |
| | Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function | Q38525468 |
| | Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 |
| | The presence of IL-17+/FOXP3+ double-positive cells in periodontitis | Q39361077 |
| | TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation | Q39645151 |
| | Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. | Q39669362 |
| | Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis | Q39714931 |
| | IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB | Q39946703 |
| | Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells | Q40107693 |
| | Inter-relationships between rheumatoid arthritis and periodontal disease. A review. | Q35212215 |
| | IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation | Q35219971 |
| | B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease | Q35222008 |
| | Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss | Q35311994 |
| | Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization | Q35441456 |
| | Parathyroid hormone: a double-edged sword for bone metabolism | Q35703582 |
| | B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo | Q35804512 |
| | Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin | Q35913720 |
| | Mechanistic insight into osteoclast differentiation in osteoimmunology | Q36073894 |
| | Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation | Q36296474 |
| | Fos/AP-1 proteins in bone and the immune system | Q36324940 |
| | TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo | Q36375923 |
| | Osteopontin in Immune-mediated Diseases | Q36377677 |
| | TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 |
| | Dendritic cells at the osteo-immune interface: implications for inflammation-induced bone loss. | Q36757614 |
| | Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma | Q36915925 |
| | Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways | Q36964283 |
| | The role of NFAT in osteoclast formation | Q37033696 |
| | Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality | Q37164404 |
| | The role of Wnt proteins in arthritis | Q37255748 |
| | Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene | Q37265676 |
| | Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation | Q37286240 |
| | Immune regulation of bone loss by Th17 cells. | Q37317215 |
| | Regulation of dendritic cell survival and cytokine production by osteoprotegerin | Q37362936 |
| | Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors | Q37438518 |
| | NF-κB signaling and bone resorption | Q37449635 |
| | Osteoimmunology and the effects of the immune system on bone | Q37626412 |
| | Regulation of haematopoietic progenitor cell proliferation and survival: The involvement of the osteoblast | Q37641682 |
| | Stromal cell-immune cell interactions | Q37809072 |
| | Signaling networks in RUNX2-dependent bone development | Q37843947 |
| | Adverse effects of corticosteroids on bone metabolism: a review | Q37875333 |
| | Interdependence of stromal and immune cells for lymph node function | Q37966310 |
| | Bone marrow niches for hematopoietic stem cells and immune cells | Q37997505 |
| | How vitamin D works on bone. | Q38033260 |
| P433 | issue | 12 | |
| P304 | page(s) | 1241-1258 | |
| P577 | publication date | 2016-09-20 | |
| P1433 | published in | Science in China. Series C: Life Sciences | Q2619480 |
| P1476 | title | Osteoimmunology: memorandum for rheumatologists | |
| P478 | volume | 59 | |